Every Spin-Off
Samyang Biopharm
0120G0 KSCompletedKRDevelops and makes medical products in South Korea, including absorbable surgical suture materials and cancer drugs using its drug-delivery technology.
Samyang Holdings spun off its pharmaceutical and bio business into Samyang Biopharm via a 인적분할 at 0.9039233:0.0960767 (effective 1 November 2025), with Samyang Biopharm re-listed on KOSPI.
- Distribution date
- 24 Nov 2025
- Structure
- Spin-off
- Parent
- Samyang Holdings (000070 KS)
- Spin-off ticker
- 0120G0 KS
- Listing
- KOSPI
- Market
- South Korea
- Sector
- Health care
- Size
- small
Source documents
- Press releaseSamsung Epis Holdings and Samyang Biopharm re-list on KOSPI (11/24/25)
- PresentationNot located
- Prospectus / demerger documentNot located
- Sourcedailypharm.com (ratio, market cap 495.2bn won on 28 Nov, 11/29/25)
- Sourceaseanexpress.co.kr (split plan and schedule, 06/05/25)
Every Spin-Off research
No report on this situation yet. New reports are published on Substack first.
Receive reports by email